Regulation Effect of Roxadustat on Blood Lipid Metabolism in Hemodialysis Patients
10.3870/j.issn.1004-0781.2023.12.010
- VernacularTitle:罗沙司他对血液透析患者血脂代谢的调节作用
- Author:
Ziqiu LIU
1
,
2
;
Ting YANG
;
Xinrui CAO
;
Lulu WANG
;
Weihong GE
Author Information
1. 南京中医药大学中西医结合鼓楼临床医学院,南京 210008
2. 南京大学医学院附属鼓楼医院药学部,南京 210008
- Keywords:
Roxadustat;
Renal anemia;
Blood lipid metabolism
- From:
Herald of Medicine
2023;42(12):1802-1807
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the regulatory effect of roxadustat on lipid metabolism while correcting anemia in hemodialysis patients.Methods Sixty patients with chronic kidney disease(CKD)receiving hemodialysis treatment at Nanjing Drum Tower Hospital and combined with concurrent renal anemia were selected.These included 30 patients receiving erythropoietin(EPO)therapy at a dose of 10 000 U per week,and 30 patients receiving roxadustat treatment at a dose based on body weight.The patients'hemoglobin levels were measured,and data on lipid and iron metabolism-related indicators were collected for statistical analysis.Results After 6 months of treatment,the mean hemoglobin levels of both groups of patients were significantly higher than the baseline levels.The mean hemoglobin level in the roxadustat group was higher than that in the EPO group(114.1±7.88 vs.122.23±10.33,P<0.05),but there was no significant difference in the achievement rate between the two groups(77%vs.93%,P>0.05).The total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),and triglycerides(TG)in the roxadustat group decreased significantly(P<0.05),while there was no significant change in the EPO group.Compared with the EPO group,roxadustat showed an improvement in iron metabolism indicators.Conclusion Roxadustat has been shown to improve lipid metabolism while correcting anemia.
